Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Health Canada’s Approach to Low Risk Veterinary Health Products: Interim Notification Pilot Program Veterinary Drugs Directorate-Health Canada Presented to the VICH Outreach Forum October, 2015 Health Canada/Veterinary Drugs Directorate Mandate Health Canada is responsible for protecting human and animal health and the safety of Canada's food supply. Through the Veterinary Drugs Directorate, Health Canada evaluates and monitors the safety, quality and effectiveness, sets standards and promotes the prudent use of veterinary drugs administered to food-producing and companion animals. http://www.hc-sc.gc.ca/dhp-mps/vet/index-eng.php 2 Health Canada/Veterinary Drugs Directorate Act , Regulations & Guidelines • The Veterinary Drugs Directorate (VDD) applies the Food and Drug Regulations under the authority of the Food and Drugs Act • Data requirements according to international guidelines for veterinary drugs • VICH 3 Health Canada/Veterinary Drugs Directorate HC-VDD website: http://www.hc-sc.gc.ca/dhpmps/vet/index-eng.php Note: Health Canada does not have authority over the practice of veterinary medicine (Provincial jurisdiction) 4 Veterinary Drug Regulation/Approval Current process Pre-market approval requirements: • • • • • Manufacturing and quality controls Animal safety data Efficacy data Human safety data (Food producing animals) http://www.hc-sc.gc.ca/dhpmps/vet/legislation/guide-ld/vdd-guide-ands-padneng.php 5 Low-risk Veterinary Health Products Issues (1) • Increased demand for low-risk veterinary health products such as vitamins, minerals, homeopathics, probiotics and botanical products among others • Members of the industry faced challenges in meeting current regulatory requirements (not adapted to these products) • Drug regulatory framework – one size fits all, regardless of risk Low-risk Veterinary Health Products Issues (2) • A number of these products marketed or imported for sale in Canada without regulatory scrutiny or appropriate market authorization • Quality, safety and efficacy unknown to Health Canada • Regulatory compliance action in Canada / at the border 7 Interim Notification Pilot Program: New Option • 2012: A voluntary option of simplified registration for LowRisk Veterinary Health Products for companion animals • Health Canada sets standards - low risk products only • Notified products have a Notification Number on label (ex. NN.1A2B) • Health Canada would not prioritize the enforcement of the regulatory requirements for such products • 8 Interim Notification Pilot Program: Development (1) Standards developed in consultation with industry and science experts • Recommendation of the Expert Advisory Committee (2010) • INPP consultation - strong stakeholder support (2011) • Flexible approach to product regulation • Reduction of administrative burden for Industry 9 Interim Notification Pilot Program: Development (2) • Administrative process in collaboration with third party administrator • Customized Database, e-forms • List of Admissible Substances • Researched over 5500 ingredients (vitamins, minerals, homeopathic, herbal, excipients etc) • Harmonization • Information from other directorates, agencies (eg NHPD, CFIA, Food) and international resources (eg US GRAS, EU directives) 10 Interim Notification Pilot Program Design (1) • Only for products intended for use in cats, dogs and horses • Great interest from stakeholders on an approach for food producing animals • Only pre-cleared ingredients • Only oral /topical/otic (ear) route of administration • Only general health claims Interim Notification Pilot Program Permitted claims General Health Claims • Refer to the maintenance of normal physiology, not to its modification • “Helps maintain”, “supports”, “enhances”, “has a role in”, “contributes to” • Not associated with a specific disease, condition or injury • Structure or physiological function • “Maintains joint and bone health” vs “Treats osteoarthritis” 12 Interim Notification Pilot Program Design (2) • Health Canada sets eligibility standards (Safety, Efficacy, Quality) • Sponsor attests to compliance (evidence on hand) • Program administered by Third Party • verifies eligibility • issues NNs • on fee-for-service basis 13 Interim Notification Pilot Program: Outcomes(1) • 700+ Notified Products since March 2012 (642 active) • 5325 ingredients permitted with qualifications ~3800 Homeopathic ~750 Non-Medicinal ~135 TCM ~640 Active (plant, animal, chemical) 14 5600 700 5400 600 5200 500 5000 400 4800 300 4600 200 4400 100 4200 0 Tuesday, September 1, 2015 Wednesday, July 1, 2015 Friday, May 1, 2015 Sunday, March 1, 2015 Thursday, January 1, 2015 Saturday, November 1, 2014 Monday, September 1, 2014 Tuesday, July 1, 2014 Thursday, May 1, 2014 Saturday, March 1, 2014 Wednesday, January 1, 2014 Friday, November 1, 2013 Sunday, September 1, 2013 Monday, July 1, 2013 Wednesday, May 1, 2013 Friday, March 1, 2013 Tuesday, January 1, 2013 Thursday, November 1, 2012 Saturday, September 1, 2012 Sunday, July 1, 2012 Tuesday, May 1, 2012 Thursday, March 1, 2012 INPP Stats No of Substances Notified Products 15 Interim Notification Pilot Program: Outcomes(2) • Use of custom made software • Database and e-forms- Product Notification, New Substance Application and Adverse Event reporting (interconnected) • Tested and fine-tuned registration model • Potential to be expanded to food producing animal products in the new regulatory framework 16 Interim Notification Pilot Program: Benefits (1) 1. Increased general safety • • • • • Low risk ingredients only Knowledge of manufacturing site (traceability/recalls) Proper labelling/manufacturing standards Adverse event reporting In/out system (Regulations still apply) 19 Interim Notification Pilot Program Benefits (2) 2. Increased access to Low-risk products for animals • Easier/faster process - reduced requirements/less costly • Low priority for regulatory compliance enforcement by Health Canada 20 Interim Notification Pilot Program: Benefits (3) 3. Reduced burden and cost for client • Simple registration process • Reduced requirement for evidence data 4. Reduced time to market for new products • 1-4 weeks vs 300 days for conventional products 5. No increase in government resources • Administration by third party 21 Interim Notification Pilot Program: Summary Reduced administrative and financial burden on Industry without compromising health and safety of Canadians and animals 22 Interim Notification Pilot Program: More info www.lrvhp.ca or http://www.hc-sc.gc.ca/dhp-mps/vet/issuesenjeux/notification-declaration-eng.php 23